AMD

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Insights from a genome-wide association study identify novel genetic loci

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

The annual ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

The first session of the 2025 COPHy meeting was titled "Big controversies in retina and beyond in 2025.”

The study considered the economic disease burden on both the patient and the caregivers, the first such study of its kind.

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

This large study sought to determine if daily supplementation with cocoa extract, a source of flavanols, reduces the occurrence or progression of AMD.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

The trial evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with aflibercept (2 mg), as per label, every 8 weeks after a loading phase for the treatment of wet AMD.

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 of its ongoing phase 1 clinical trial of TH103 in treatment-naïve nAMD patients in the second half of 2025.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that was followed by a TAE.

Among the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition.

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

Retina Resource was developed by retina specialists for retina specialists.

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type.”